checkAd
    Startseite > Aktien > Cidara Therapeutics > Nachrichten
    Cidara Therapeutics Aktie
    12,340
     
    USD
    +16,20 %
    +1,720 USD
    Letzter Kurs 02:00:00 Nasdaq
    12,330
     
    USD
    200 STK
    Geldkurs 22.05.24
    12,500
     
    USD
    6.800 STK
    Briefkurs 22.05.24
    ISIN: US1717572069 · WKN: A3D4A6 · SYM: CDTX · USA

    Neueste Nachrichten

    Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
    26.04.24 · globenewswire · Cidara Therapeutics
    CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
    25.04.24 · Business Wire (engl.) · Cidara Therapeutics
    Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
    24.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
    24.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    22.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
    22.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Reverse Stock Split
    22.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
    05.04.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
    06.03.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
    12.02.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
    29.01.24 · globenewswire · Cidara Therapeutics
    Cidara Therapeutics Announces European Approval of REZZAYO (rezafungin) for the Treatment of Invasive Candidiasis in Adults
    22.12.23 · globenewswire · Cidara Therapeutics